德达博妥单抗三阴乳腺癌一线治疗新突破

医药地理
Oct 09, 2025

10月6日,阿斯利康宣布TROP2靶向ADC德达博妥单抗(Datroway)在III期TROPION-Breast02研究中,作为免疫治疗不适用的局部复发性不可手术或转移性三阴性乳腺癌(TNBC)一线治疗,与化疗相比,在总生存期(OS)上取得了统计学显著且具有临床意义的改善,成为首个也是唯一一个在该人群中实现显著OS获益的治疗方案。德达博妥单抗在双重主要终点之一的无进展生存期(PFS)方面也显示出...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10